Articles On Imugene (ASX:IMU)

Cancer-fighter Imugene has received positive feedback from the US Food and Drug Administration on its proposed trials and commercial manufacture of “Azer-cel” to treat patients with certain blood cancers.

Cancer-fighter Imugene has received positive feedback from the US Food and Drug Administration on its proposed trials and commercial manufacture of “Azer-cel” to treat patients with certain blood cancers.

Lumos granted approvals by the US FDA for the ViraDx test Imugene receives positive feedback from FDA for CAR T cell therapy Genetic Technology expands its geneType Multi-Risk Test in Australia   Lumos granted US FDA approval for ViraDx M...

Imugene (ASX: IMU) has announced positive feedback from the US Food and Drug Administration (FDA) on a manufacturing process for lead candidate azer-cel (azercabtagene zapreleucel or allogeneic CD19 CAR T) for the treatment of patients with...

ASX futures were predicting the ASX will open slightly in the green to start the week in pre-morning trades, up 4 points. This comes on the back of a mostly green US Friday close as investors shift their focus to incoming US inflation da...

It ended up being a pretty lousy Tuesday for the S&P/ASX 200 Index (ASX: XJO) on the markets today. After yesterday’s positive start to the trading week, the ASX 200 took a backwards step during today...

Imugene (IMU) announces the clearance of the first cohort in its phase one MAST trial The trial is evaluating the safety of its novel cancer-killing virus, VAXINIA) As a result, Imugene is now recruiting its second cohort to test each...

Imugene has revealed that the phase-one trial of its anti-cancer virus “Vaxinia”, which is administered directly into the tumour, has passed the first cohort of its study, clearing the way for a second phase.

Sydney-headquartered clinical stage immuno-oncology specialist Imugene (ASX: IMU) continues to build momentum both scientifically and corporately with a number of new developments. On the science side, Imugene has made further strong progre...

It’s that time of the year again when S&P Dow Jones Indices announces the rebalance of the S&P/ASX Indices. According to the release, there will be a total of five companies entering the S&P/ASX 200 Index (ASX: XJO) at the n...

Futures indicate the ASX200 will open slightly higher as a new trading week commences, driven by growing confidence that the US Federal Reserve will pause at its next rates meeting due to the increase in unemployment in the country. In A...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Clinical stage immuno-oncology specialist Imugene (ASX: IMU) has added another key appointment to its growing team of specialists. Dr John Byon has been named as senior vice president of clinical development, bringing a wealth of experience...

The S&P/ASX 200 Index (ASX: XJO) has recorded yet another gain today, albeit one not quite on the same levels as yesterday. Still, the ASX 200 has now risen every day this week so far, with today makin...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

We’ve just had another mighty fine day for the S&P/ASX 200 Index (ASX: XJO) this Wednesday. After rising enthusiastically over both Monday and Tuesday, buying really stepped on the gas today. By the clo...

At the start of each week, I like to look at ASIC’s short position report to find out which shares are being targeted by short sellers. This is because I believe it is well worth keeping a close eye on short interest levels as high lev...

Neuren’s US FDA approval for trofinetide has seen its share price boosted ~130% in past year   Eye disease specialist Opthea is undertaking two Phase 3 trials to treat Wet AMD with results due in mid 2024 Anteris Technologies is developing...

With so many shares to choose from on the ASX, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you. Three top ASX shares that leading brokers have named...

Fresh from a strongly supported $35 million placement, ASX-listed immuno-oncology medtech Imugene is on a steadfast mission to activate the immune system of cancer patients to help treat and eradicate tumours.

Telstra Group Ltd (ASX: TLS) shares and Vanguard Australian Shares High Yield ETF (ASX: VHY) are both known for paying dividend income to investors. In this article, I’m going to look at which one could be the better choice for passive i...

By Greg Peel Choosing to Follow On It was a rock’n’roll session on the ASX200 on Friday, ahead of a flat close. The futures had said down -28 on Wall Street weakness, the ASX200 fell -22 points on the open, but by 12.30pm was up 21. Then it...

The pre-eminent benchmark of the Australian share market, the S&P/ASX 200 Index (ASX: XJO), narrowly avoided its third consecutive negative session on Friday. Today’s feeble finish to the week coincides with a financial milestone for C...

The ASX200 had a stronger session than expected, closing up, but only just. The real estate sector led the way gaining 1.8 per cent, utilities were also up by a per cent and materials just short of a per cent. In the green Goodman...

ASX 200 benchmark falls, gains and wanes its way to just 0.03% for the day. Real Estate, resources and gold (oh my!) lead a troubled bourse from disaster. Mining tech minnow Orexplore’s $1.55m BHP deal delivers a +150% gift for investors....

It has been another busy week for Australia’s top brokers. This has led to the release of a large number of broker notes. Three broker buy ratings that you might want to know more about are summarised below. Here’s why brokers think th...

The S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain on Friday. In afternoon trade, the benchmark index is up 0.1% to 7,154.3 points. Four ASX shares that have failed to follow the market higher today are listed below...

The ASX200 has gone against expectations and lifted ever so slightly by 0.1 of a per cent mid-session. Real estate led gainers – up nearly 1.5 per cent – but the heat was on communications and consumer discretionary which have both shed...

Building a portfolio of ASX shares that will pay you a generous income stream is a hard task. After all, there are hundreds of dividend-paying shares on the ASX, and trying to pick the right ones can be overwhelming. So to make the process...

The Abacus Property Group (ASX: ABG) share price is ending the week on a high. In morning trade, the ASX 200 real estate share is up 8% to $1.17. This follows the release of Abacus Property Group’s FY 2023 results. ASX 200 real estate sh...

Sydney-headquartered Imugene (ASX: IMU) has made a strong start to a $65 million capital raising aimed at supporting its global growth plans. The transformative cancer medicine developer has received firm commitments for the first phase of...

Stockhead’s Top 10 at 11, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Imugene (IMU) receives firm commitments to raise $35 million through a share placement and will initiate an SSP for existing shareholders The placement comprises the issuance of 416.7 million new shares at 84 cents apiece, while the SSP...

The Imugene Limited (ASX: IMU) share price has returned from its trading halt and dropped deep into the red. At the time of writing, the immuno-oncology company’s shares are down 15% to 8 cents. Why is the Imugene share price sinking? Th...

Australian company Imugene (ASX:IMU) has agreed with US-based Precision Biosciences to acquire a worldwide exclusive license to its azer-cel allogeneic CD19 CAR-T cell therapy program.

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

After a steep early drop, the benchmark stabilised to close 1.5% down. InfoTech and Materials fared worst, following a mega tech sell-off on Wall Street. Loyal Lithium soared more than 37% after hitting fresh spod at Trieste.   I think we...

On Wednesday, the ASX experienced a significant drop in response to a global sell-off that took place overnight. At the closing bell, the S&P/ASX 200 was 1.5 per cent lower at 7,195.20. This decline was mirrored by the All Ordinaries in...

Imugene (IMU) enters an agreement with Precision Biosciences to acquire an exclusive worldwide license for the latter’s azer-cel allogeneic CD19 CAR T cell therapy program It gives the company the potential to initiate a registrational s...

We’re smack bang in the middle of ASX earnings season right now. And with earnings comes new dividend announcements from many S&P/ASX 300 Index (ASX: XKO) shares and by extension, ex-dividend dates. What does ex-dividend mean? Whenever...

  AML3D (ASX:AL3) has received a $2M order from US Navy for submarine parts. In response, interim CEO Sean Ebert said: “AML3D’s focus is on the US defence, aviation and maritime sectors and the company is well positioned to access the many...

China's shift towards deflation is causing concern in financial markets, yet some money managers suggest potential positive outcomes, as lower prices stemming from China's role as a major global producer could lead to reduced costs worldwid...

Clinical-stage immuno-oncology company Imugene (ASX: IMU) has entered into an agreement with US-based Precision Biosciences to acquire a worldwide licence to Precision’s azer-cel (azercabtagene zapreleucel) allogeneic CD19 CAR T cell therap...

Clinical-stage immuno-oncology company Imugene (ASX: IMU) has entered into an agreement with US-based Precision Biosciences to acquire a worldwide licence to Precision’s azer-cel (azercabtagene zapreleucel) allogeneic CD19 CAR T cell therap...

The money will be used to fund the acquisition of a license for Precision Biosciences’ azer-cel allogeneic cancer treatment.

Futures are predicting that the ASX will open lower this morning, following losses across Europe and Wall Street overnight, compounded by China’s troubling economic outlook. However, amid this backdrop, the US reported robust retail sale...

16 Aug 2023 - A snapshot of the stocks on the move, featuring AML3D (ASX:AL3), Imugene (ASX:IMU) and Loyal Lithium (ASX:LLI).

The ASX200 closed the day 0.86 per cent lower with almost all sectors in the red except communications, IT and energy. Helping boost the energy sector gains was Woodside Energy, up more than a per cent while Job hunting platform Seek gai...

It was a depressing start to the trading week for the S&P/ASX 200 Index (ASX: XJO) this Monday. Following on from Friday’s losses, ASX 200 investors stepped on the gas when it came to selling today. By the end of t...

With so many shares to choose from on the ASX, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you. Three top ASX shares that leading brokers have named...